DealShot: Orchid Asia Leads $50M Series D Round In Chinese Podcast Sharing Platform Lizhi.FM

Follow Us:

China Money Network’s DealShot provides detailed information on venture capital and private equity deals in China on a daily basis.

Here you can find out where Chinese investors have been investing their money in at around 5pm each workday.

CompanyRoundAmountLead InvestorParticipantsCompany Intro
XpressBeesStrategic financingUS$100 millionAlibaba GroupXpressBees is a Pune, India-based e-commerce logistics company, providing same/next day delivery, cash on delivery and other customized logistics solutions in India.
Lizhi.FMSeries DUS$50 millionOrchid Asia GroupEvolution Media ChinaLizhi.FM is a Chinese radio mobile app developer and podcast sharing platform.
Guomai MediaSeries B, Series CUS$45.7MIDG Capital, Bona Film Group Ltd.Aqua Ventures, HG Capital, Matrix Partners ChinaGuomai publishes multi-media cultural products for the new middle class in the categories of literature, history, science and religion.
AISECStrategic financingUS$15 millionTencent HoldingsAISEC is a Chinese network security service provider. Its core products include security detection system AIScanner and intrusion detection system WebIDS.
Yimi StationPre-ATens of millions of RMBundisclosedYimi Station is a Shenzhen-based smart food ordering platform. Users can place orders online and food will be delivered to a nearby smart food box, which has automatic temperate control and can be opened with QR code.
Cihon.cnSeries BundisclosedMarathon Venture Partners, Dongfeng Asset Management Co., LtdCihon is a Beijing-based car data provider for carmakers, car insurers and other third-party service providers.
Huada Empyrean SoftwareStrategic financingUS$15 millionNational Small and Medium-size Enterprises Development Fund (Shenzhen Guozhong Venture Capital Management Co., Ltd)China Electronics Corporation, Shenzhen Venture Capital GroupHuada Empyrean Software is a Beijing-based electronic design automation (EDA) software developer and solution provider.
Frontier BiotechSeries CUS$48 millionBeijing Huaxin Century Investment Group Co., LtdShenzhen Capital Group Co., Ltd, Efung CapitalFrontier Biotech is a Nanjing-based clinical stage pharmaceutical company. It has developed a long-acting peptide drug discovery and development platform that could potentially transform any peptide drug into long-acting agent.

Related News

Leave a Reply

Your email address will not be published. Required fields are marked *